我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

脂联素的生物学作用及临床应用

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2013年第1期
页码:
90-092
栏目:
综述
出版日期:
2013-02-25

文章信息/Info

Title:
Biological functions and clinical implications of adiponectin
作者:
姜 博1赵璧君2程 亮2任 恺2王 云1王红兵2易 蔚2
(1.宁夏医科大学附属总院胸心外科,宁夏 银川 750004;2.第四军医大学西京医院心血管外科,陕西 西安 710032)
Author(s):
JIANG Bo1 ZHAO Bijun2 CHENG Liang2 REN Kai2 WANG Yun1 WANG Hongbing2 YI Wei2
(1.Department of Cardiothoracic Surgery, General Hospital, Ningxia Medical University, Yinchuan 750004, Ningxia, China; 2.Department of Cardiovascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, Shaanxi, China)
关键词:
脂联素脂肪细胞生物学作用临床应用
Keywords:
adiponectin adipokines cardioprotection metabolism biomarker
分类号:
R589.2
DOI:
-
文献标识码:
A
摘要:
脂联素(adiponectin,APN)是一种脂肪细胞为主分泌的细胞因子,已证实其具有调节代谢、血管内皮保护、抗炎症反应及心肌细胞保护等多种生物学作用,并发现其也可作为潜在的心血管疾病的生物学标志物。本文根据基础医学、转化医学研究的结果及临床流行病学数据,综述了APN的生物学作用及其临床应用前景。
Abstract:
Adiponectin is one of the key adipokines. Identified biological functions of adiponectin include metabolic regulation, vascular protection, antiinflammation and cardioprotective actions. Numerous clinical studies have demonstrated that adiponectin is one potential biological marker of cardiovascular diseases. In the present review, the biological functions and clinical prospect of adiponectin are discussed based on the findings of basic science and translational medicine along with clinical epidemiological data.

参考文献/References

[1]樊 荣,臧益民.脂肪组织的功与过评述[J].心脏杂志,2008,20(3):370-371.

[2]Davis KE,Scherer PE.Adiponectin:no longer the lone soul in the fight against insulin resistance?[J].Biochem J,2008,416(2):e7-e9.

[3]Denzel MS,Scimia MC,Zumstein PM,et al.Tcadherin is critical for adiponectinmediated cardioprotection in mice[J].J Clin Invest,2010,120(12):4342-4352.

[4]Halberg N,Schraw TD,Wang ZV,et al.Systemic fate of the adipocyte derived factor adiponectin[J].Diabetes,2009,58(9):1961-1670.

[5]Brown JE,Conner AC,Digby JE,et al. Regulation of betacell viability and gene expression by distinct agonist fragments of adiponectin[J].Peptides,2010,31(5):944-949.

[6]Holland WL,Miller RA,Wang ZV,et al.Receptormediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin[J].Nat Med,2011,17(1):55-63.

[7]Sharma K,Ramachandrarao S,Qiu G,et al.Adiponectin regulates albuminuria and podocyte function in mice[J].J Clin Invest,2008,118(5):1645-1656.

[8]Lo MM,Salisbury S,Scherer PE,et al.Serum adiponectin complexes and cardiovascular risk in children with chronic kidney disease[J].Pediatr Nephrol,2011,26(11):2009-2017.

[9]Yamauchi T,Nio Y,Maki T,et al.Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions[J].Nat Med,2007,13(3):332-339.[10]Polyzos SA,Toulis KA,Goulis DG,et al.Serum total adiponectin in nonalcoholic fatty liver disease:a systematic review and metaanalysis[J]. Metabolism,2011,60(3):313-326.

[11]Ge Q,Ryken L,Noel L,et al.Adipokines identified as new downstream targets for adiponectin:lessons from adiponectinoverexpressing ordeficient mice[J].Am J Physiol Endocrinol Metab,2011,301(2):E326-E335.

[12]Tian L,Luo N,Klein RL,et al. Adiponectin reduces lipid accumulation in macrophage foam cells[J].Atherosclerosis,2009,202(1):152-161.

备注/Memo

备注/Memo:
收稿日期: 2012-07-09.基金项目:国家自然科学基金青年项目资助(81100137) 通讯作者:易蔚,主治医师,主要从事脂肪细胞因子心血管保护的研究Email:yiwei@fmmu.edu.cn 作者简介:姜博,住院医师,硕士生Email:jiangbolml@163.com
更新日期/Last Update: 2013-03-20